Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: The incidence of multidrug-resistant (MDR) chronic hepatitis B (CHB) during sequential lamivudine (LAM) and adefovir dipivoxil (ADV) treatment is increasing. We investigated the antiviral efficacies of various rescue regimens in patients who failed sequential LAM-ADV treatment. Methods: Forty-eight patients (83.3% of whom were HBeAg-positive) who failed sequential LAM-ADV treatment were treated with one of the following regimens: entecavir (ETV) (1 mg) monotherapy (n=16), LAM+ADV combination therapy (n=20), or ETV (1 mg)+ADV combination therapy (n=12). All patients had confirmed genotypic resistance to both LAM and ADV and were evaluated every 12 weeks. Results: The baseline characteristics and treatment duration did not differ significantly among the study groups. During the treatment period (median duration: 100 weeks), the decline of serum HBV DNA from baseline tended to be greatest in the ETV+ADV group at all-time points (week 48: -2.55 log10 IU/mL, week 96: -4.27 log10 IU/mL), but the difference was not statistically significant. The ETV+ADV group also tended to have higher virologic response rates at 96 weeks compared to the ETV monotherapy or LAM+ADV groups (40.0% vs. 20.0% or 20.0%, P=0.656), and less virologic breakthrough was observed compared to the ETV monotherapy or LAM+ADV groups (8.3% vs. 37.5% or 30.0%; P =0.219), but again, the differences were not statistically significant. HBeAg loss occurred in one patient in the ETV+ADV group, in two in the ETV monotherapy group, and in none of the LAM+ADV group. The safety profiles were similar in each arm. Conclusions: There was a nonsignificant tendency toward better antiviral efficacy with ETV+ADV combination therapy compared to LAM+ADV combination therapy and ETV monotherapy for MDR CHB in Korea, where tenofovir is not yet available. (Clin Mol Hepatol 2013;19:29-35)
Abstract
Background/Aims: The incidence of multidrug-resistant (MDR) chronic hepatitis B (CHB) during sequential lamivudine (LAM) and adefovir dipivoxil (ADV) treatment is increasing. We investigated the antiviral efficacies of various rescue regimens in patients who failed sequential LAM-ADV treatment. Methods: Forty-eight patients (83.3% of whom were HBeAg-positive) who failed sequential LAM-ADV treatment were treated with one of the following regimens: entecavir (ETV) (1 mg) monotherapy (n=16), LAM+ADV combination therapy (n=20), or ETV (1 mg)+ADV combination therapy (n=12). All patients had confirmed genotypic resistance to both LAM and ADV and were evaluated every 12 weeks. Results: The baseline characteristics and treatment duration did not differ significantly among the study groups. During the treatment period (median duration: 100 weeks), the decline of serum HBV DNA from baseline tended to be greatest in the ETV+ADV group at all-time points (week 48: -2.55 log10 IU/mL, week 96: -4.27 log10 IU/mL), but the difference was not statistically significant. The ETV+ADV group also tended to have higher virologic response rates at 96 weeks compared to the ETV monotherapy or LAM+ADV groups (40.0% vs. 20.0% or 20.0%, P=0.656), and less virologic breakthrough was observed compared to the ETV monotherapy or LAM+ADV groups (8.3% vs. 37.5% or 30.0%; P =0.219), but again, the differences were not statistically significant. HBeAg loss occurred in one patient in the ETV+ADV group, in two in the ETV monotherapy group, and in none of the LAM+ADV group. The safety profiles were similar in each arm. Conclusions: There was a nonsignificant tendency toward better antiviral efficacy with ETV+ADV combination therapy compared to LAM+ADV combination therapy and ETV monotherapy for MDR CHB in Korea, where tenofovir is not yet available. (Clin Mol Hepatol 2013;19:29-35)
참고문헌 (25)
- Lavanchy D, "Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures", J Viral Hepat, 11, pp.97~107 (2004)
- Yim HJ, "Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005", Hepatology, 43(2 Suppl 1), pp.S173~S181 (2006)
- Ahn SH, "Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions", Hepatol Int, 4, pp.386~395 (2010)
- Holomán J, "EASL clinical practice guidelines", J Hepatol, 51, pp.821~822 (2009)
- Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B", Gastroenterology, 125, pp.1714~1722 (2003)
- Chen Y, "Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B", Int J Infect Dis, 16, pp.e152~e158 (2012)
- Yim HJ, "Evolution of multi-drug resistant hepatitis B virus during sequential therapy", Hepatology, 44, pp.703~712 (2006)
- Kuo A, "Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B", Clin Gastroenterol Hepatol, 2, pp.266~272 (2004)
- van Bömmel F, "Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside", nucleotide analogues, 2010, pp.51, 73~80
- Chon YE, "Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B", Antivir Ther, 16, pp.469~477 (2011)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- European Association For The Study Of The Liver, "EASL clinical practice guidelines. Management of chronic hepatitis B", Gastroenterol Clin Biol, 33, pp.539~554 (2009)
- Hoofnagle JH, "Management of hepatitis B", summary of a clinical research workshop, 45, pp.1056~1075 (2007), Hepatology
- Lee JM, "Longterm adefovir dipivoxil monotherapy for up to 5 years in lamivudineresistant chronic hepatitis B", Antivir Ther, 15, pp.235~241 (2010)
- Han KH, "Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B", Antivir Ther, 16, pp.77~87 (2011)
- Perrillo R, "Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus", Gastroenterology, 126, pp.81~90 (2004)
- Ryu HJ, "Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudineresistant chronic hepatitis B", J Med Virol, 82, pp.1835~1842 (2010)
- Benhamou Y, "Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus", N Engl J Med, 348, pp.177~178 (2003)
- Patterson SJ, "Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B", Gut, 60, pp.247~254 (2011)
- Ahn SH, "Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions", Hepatol Int, 4, pp.386~395 (2010)
- Rapti I, "Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAgnegative chronic hepatitis B", Hepatology, 45, pp.307~313 (2007)
- Inoue J, "Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern", J Viral Hepat, 18, pp.206~215 (2011)
- Kwak MS, "Longterm efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir", J Viral Hepat, 18, pp.e432~e438 (2011)
- Chen CH, "Evo lution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance", J Hepatol, 52, pp.478~485 (2010)
- Heo NY, "Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir", J Hepatol, 53, pp.449~454 (2010)